ciltacabtagene autoleucel

AXP000018.1 · CAR-T cell therapy

Platform
autologous CAR-T
Targets
TNFRSF17
Originator
Legend Biotech
Sponsor
Janssen (Johnson & Johnson); Legend Biotech

Names

NameTypeSource
ciltacabtagene autoleucelpreferred name, INNcurator, ncit
Carvyktibrandncit
JNJ-4528codepress
JNJ-68284528codencit
LCAR-B38Mcodencit
cilta-celsynonymncit

Virus

Role
Ex vivo gene transfer
Family
Retroviridae
Virus
lentivirus
Replication
non replicating
Modifications
replication-incompetent lentiviral vector; the CAR carries two single-domain antibodies, giving two BCMA-binding domains, with 4-1BB costimulatory and CD3 zeta signalling domains
Transgenes
anti-BCMA chimeric antigen receptor (bivalent)
Route
ex vivo, intravenous
Carrier
autologous T cells
Source
evidence

Cross-references

NCI Thesaurus
C148498
Wikidata
Q111948874
FDA UNII
0L1F17908Q

Approvals

AgencyRegionDateStatusBrandIndicationSource
FDAUS2022-02-28approvedCarvyktiAdults with relapsed or refractory multiple myeloma after at least one prior line including a proteasome inhibitor and an immunomodulatory agent, and refractory to lenalidomidesource
EMAEU2022-05-25approvedCarvyktiAdults with relapsed and refractory multiple myeloma after at least one prior therapy including an immunomodulatory agent and a proteasome inhibitor, who progressed on the last therapy and are refractory to lenalidomidesource
PMDAJP2022-09-26approvedCarvyktiRelapsed or refractory multiple myeloma in patients with no prior BCMA-directed CAR T-cell therapy who have had at least three prior lines including an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 antibody, and who did not respond to or relapsed after the last of themsource

Clinical trials (22)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT07725406Low-Dose TBI Plus CAR T-Cell Therapy for Relapsed/Refractory DLBCL and Multiple MyelomaRecruitingPhase 12026-112028-08-0132Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL); Relapsed or Refractory Multiple Myeloma (MM)
NCT07093554Cilta-Talq Fusion Study: A Phase 1b Study of Talquetamab Bridging Therapy Followed by Ciltacabtagene Autoleucel in Patients With Relapsed/Refractory Multiple MyelomaRecruitingPhase 12025-12-022027-07-0131Refractory Multiple Myeloma; Relapse Multiple Myeloma
NCT07149857A Study to Evaluate Efficacy and Safety of Ciltacabtagene AutoleucelRecruitingPhase 22025-10-032028-04-1260Multiple Myeloma
NCT06940297Dasatinib and Quercetin With CAR-T Therapy for the Treatment of Patients With Relapsed or Refractory Multiple MyelomaRecruitingPhase 22025-09-182031-08-1544Recurrent Multiple Myeloma; Refractory Multiple Myeloma
NCT06855121The Norwegian Immunotherapy in Multiple Myeloma StudyRecruiting2025-01-152029-01400AL Amyloidosis; Myeloma Multiple; Plasma Cell Leukemia
NCT06623630Lymphodepleting Total Body Irradiation (TBI) Plus Cyclophosphamide Prior to Ciltacabtagene Autoleucel (Carvykti; Cilta-cel) for Multiple Myeloma (MM) Patients With Impaired Renal FunctionRecruitingPhase 12024-12-042027-06-3016Multiple Myeloma
NCT06574126Ciltacabtagene Autoleucel in High-Risk Smoldering Multiple MyelomaRecruitingPhase 22024-09-302032-09-3020High Risk Smoldering Multiple Myeloma
NCT06550895A Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple MyelomaActive not recruitingPhase 22024-09-162027-08-2611Multiple Myeloma
NCT06577025A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple MyelomaActive not recruitingPhase 22024-08-202030-09-0243Multiple Myeloma
NCT05666700CAR-T Cell Therapy in RelApsed/Refractory Myeloma With ExtrameduLlary Disease - an in Vivo Imaging and Molecular Monitoring StudyActive not recruitingPhase 12023-12-082027-0110Extramedullary Myeloma
NCT05257083A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple MyelomaActive not recruitingPhase 32023-10-102033-06759Multiple Myeloma
NCT05767359CAR- PRISM (PRecision Intervention Smoldering Myeloma)Active not recruitingPhase 22023-04-192025-12-1520Multiple Myeloma; Smoldering Multiple Myeloma
NCT05347485A Study of JNJ-68284528 Out-of-Specification (OOS) for Commercial Release in Participants With Multiple MyelomaCompletedPhase 22022-05-132023-11-3086Multiple Myeloma
NCT05201781A Long-term Study for Participants Previously Treated With Ciltacabtagene AutoleucelRecruitingPhase 42022-03-092037-07-29295Multiple Myeloma
NCT04923893A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial TherapyActive not recruitingPhase 32021-08-192029-02-14743Multiple Myeloma
NCT04181827A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple MyelomaActive not recruitingPhase 32020-06-122024-05-01419Multiple Myeloma
NCT04133636A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple MyelomaActive not recruitingPhase 22019-11-072027-02-26208Multiple Myeloma
NCT03758417A Study of LCAR-B38M CAR-T Cells, a Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Chinese Participants With Relapsed or Refractory Multiple MyelomaTerminatedPhase 22019-01-232025-07-10123Multiple Myeloma
NCT03548207A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-Cell Maturation Antigen (BCMA) in Participants With Relapsed or Refractory Multiple MyelomaCompletedPhase 1/22018-06-292022-08-23126Multiple Myeloma
NCT03090659LCAR-B38M Cells in Treating Relapsed/Refractory (R/R) Multiple MyelomaUnknownPhase 1/22015-10-022023-12-31100Refractory or Relapsed Multiple Myeloma
NCT05346835Expanded Access Program (EAP) for Ciltacabtagene Autoleucel (Cilta-Cel) Out-of-Specification (OOS) in Participants With Multiple MyelomaAvailableMultiple Myeloma
NCT04452994Individual Patient Investigational New Drug (IND) Expanded Access Program of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy for Participant With Multiple MyelomaNo longer availableMultiple Myeloma
Unconfirmed matches (2)

Trials that mention one of the names in a weaker way (a code only in the title, a short or ambiguous name). Not counted above.

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditionsMatched by
NCT07200089Recombinant Human IL-7 (NT-I7) in Relapsed/Refractory Multiple Myeloma Following BCMA CAR-T Therapy (Cilta-cel)RecruitingPhase 12026-06-052028-03-1052Multiple Myeloma; Multiple Myeloma in Relapse; Multiple Myeloma, Refractoryname in title: cilta-cel
NCT06947083Elranatamab Post Cilta-cel in Patients With Clinical High Risk Relapsed MyelomaRecruitingPhase 22025-05-272029-0439Myelomaname in title: cilta-cel

Recent changes

No changes recorded in its trials yet.

Clinical papers

PubMedTitleJournalYearLinked by
PMID 40637727Cytopenias and infections following ciltacabtagene autoleucel in heavily pretreated relapsed or refractory multiple myeloma.Haematologica2026name in title: ciltacabtagene autoleucel
PMID 41139561Real-World Efficacy Outcomes of Ciltacabtagene Autoleucel in Relapsed Refractory Multiple Myeloma: A Comparative Study with the Cartitude-1 Trial.Clinical lymphoma, myeloma & leukemia2026name in title: ciltacabtagene autoleucel
PMID 41257522Treatment-Emergent Parkinsonism in Four Patients Treated with Chimeric Antigen Receptor T-Cell Therapy.Movement disorders clinical practice2026name in abstract: ciltacabtagene autoleucel
PMID 41519141Cilta-cel in lenalidomide-refractory multiple myeloma (CARTITUDE-4): an updated analysis including overall survival from an open-label, multicentre, randomised, phase 3 trial.The Lancet. Oncology2026cited by trial NCT04181827
PMID 41592291Ruxolitinib for ciltacabtagene autoleucel-associated refractory diarrhea.Blood2026name in title: ciltacabtagene autoleucel
PMID 41627370Ciltacabtagene Autoleucel Versus Idecabtagene Vicleucel in Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma with 2-4 Prior Lines of Therapy: Updated Matching-Adjusted Indirect Comparison.Advances in therapy2026cited by trial NCT03548207
PMID 41824255Validation of the Multiple Myeloma Symptom and Impact Questionnaire (MySIm-Q) in patients with multiple myeloma who were enrolled in the CARTITUDE-4 trial.Journal of patient-reported outcomes2026cited by trial NCT04181827
PMID 41853755Delayed fatal neurotoxicity in post CAR-T cell therapy for multiple myeloma, a case report.Leukemia research reports2026name in abstract: ciltacabtagene autoleucel
PMID 41886677Multiomic and Longitudinal Dissection of Immune Dynamics Associated with Parkinsonism after Ciltacabtagene Autoleucel Therapy.Blood cancer discovery2026name in title: ciltacabtagene autoleucel
PMID 41914448Navigating the Post-BCMA/GPRC5D Landscape: Efficacy of Selinexor, Bortezomib, and Dexamethasone After Sequential Immunotherapy Failure in Penta-Refractory Multiple Myeloma-A Multicenter Analysis.American journal of hematology2026name in abstract: ciltacabtagene autoleucel
PMID 41980929Safety and efficacy of ciltacabtagene autoleucel for relapsed/refractory multiple myeloma: a CIBMTR study.Blood cancer journal2026name in title: ciltacabtagene autoleucel
PMID 42004656Minimal Change Disease Following B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T-Cell Therapy.Kidney medicine2026name in abstract: ciltacabtagene autoleucel
PMID 42004964Reversible cerebral vasoconstriction syndrome following ciltacabtagene autoleucel therapy for relapsed multiple myeloma: a case report.Frontiers in immunology2026name in title: ciltacabtagene autoleucel
PMID 42010117Ciltacabtagene autoleucel in high-risk smoldering multiple myeloma: the CAR-PRISM phase 2 trial.Nature medicine2026cited by trial NCT05767359
PMID 42084945Detection of cytokine release syndrome using wearables and cytokine profiling following CAR-T therapy for myeloma.JCI insight2026name in abstract: ciltacabtagene autoleucel
PMID 42253352Peripheral Nerve Infiltration by CAR T-cells in a Case of Mononeuritis Multiplex after Ciltacabtagene Autoleucel.Blood cell therapy2026name in title: ciltacabtagene autoleucel
PMID 42284467Outcomes of CAR T-cell Therapy and Bispecific Antibodies as Single-Modality and Sequential Strategies in Relapsed/Refractory Multiple Myeloma.Blood cancer discovery2026name in abstract: ciltacabtagene autoleucel
PMID 42351384Early Treatment Failure in Patients Receiving Ciltacabtagene-Autoleucel for Relapsed/Refractory Multiple Myeloma.American journal of hematology2026name in title: ciltacabtagene autoleucel
PMID 42370651Healthcare resource utilization and costs in patients with multiple myeloma administered ciltacabtagene autoleucel in outpatient versus inpatient settings after one to three prior lines of therapy.Journal of comparative effectiveness research2026name in title: ciltacabtagene autoleucel
PMID 42379467Kidney Transplantation Post-Chimeric Antigen Receptor (CAR) T-Cell Therapy in Multiple Myeloma.American journal of kidney diseases : the official journal of the National Kidney Foundation2026name in abstract: ciltacabtagene autoleucel
PMID 42392508Impact of Disease Biology and Bridging Strategy on Outcomes After CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma.Transplantation and cellular therapy2026name in abstract: ciltacabtagene autoleucel
PMID 42444648Steroid-resistant bilateral facial nerve palsies, ophthalmoparesis, and multilevel thoracic radiculopathy as immune effector cell-associated late-onset neurotoxicity after cilta-cel CAR-T therapy: a case report and review of similar cases.Frontiers in neurology2026name in title: cilta-cel
PMID 42645380Overcoming Trial Exclusion: A Multicenter Analysis of Hemodialysis Multiple Myeloma Patients Who Underwent BCMA-Directed CAR-T Therapy.Current oncology (Toronto, Ont.)2026name in abstract: ciltacabtagene autoleucel
PMID 42747560Early deep response to cilta-cel as 2nd CAR T-Cell therapy after CELMoD-based bridging for advanced multiple myeloma.Annals of hematology2026name in title: cilta-cel
PMID 42777241Phase 1 Study of Anito-cel, a d-Domain BCMA CAR T Cell for Refractory or Recurrent Myeloma.The New England journal of medicine2026name in abstract: ciltacabtagene autoleucel
PMID 42780369Sequential Autologous Stem Cell Transplantation and Ciltacabtagene Autoleucel for Concurrent Multiple Myeloma and Presumptive Immunoglobulin Heavy- and Light-Chain Amyloidosis in a Patient With Systemic Lupus Erythematosus.Cureus2026name in title: ciltacabtagene autoleucel
PMID 42860893Plain language summary of the long-term (5 or more years) outcomes in the CARTITUDE-1 trial of ciltacabtagene autoleucel in people with relapsed or refractory multiple myeloma.Future oncology (London, England)2026cited by trial NCT03548207
PMID 42871407Markedly Delayed Onset ICANS in the Setting of CAR T-Cell-Mediated Aseptic Meningoencephalitis: Two Cases.The Neurohospitalist2026name in abstract: ciltacabtagene autoleucel
PMID 39365257Safety and efficacy of standard-of-care ciltacabtagene autoleucel for relapsed/refractory multiple myeloma.Blood2025name in title: ciltacabtagene autoleucel
PMID 39756844Patient-reported outcomes following ciltacabtagene autoleucel or standard of care in patients with lenalidomide-refractory multiple myeloma (CARTITUDE-4): results from a randomised, open-label, phase 3 trial.The Lancet. Haematology2025cited by trial NCT04181827
PMID 39938094CAR+ T-Cell Lymphoma after Cilta-cel Therapy for Relapsed or Refractory Myeloma.The New England journal of medicine2025cited by trial NCT04181827
PMID 39965175Comparison of Standard-of-Care Idecabtagene Vicleucel and Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology2025name in title: ciltacabtagene autoleucel
PMID 39984633Multiomic profiling of T cell lymphoma after therapy with anti-BCMA CAR T cells and GPRC5D-directed bispecific antibody.Nature medicine2025name in abstract: ciltacabtagene autoleucel
PMID 40163799Cyclophosphamide mitigates non-ICANS neurotoxicities following ciltacabtagene autoleucel treatment.Blood2025name in title: ciltacabtagene autoleucel
PMID 40178605Successful sequential application of CAR T-cell-therapies in relapsed refractory multiple myeloma.Annals of hematology2025name in abstract: ciltacabtagene autoleucel
PMID 40354013Comparative Efficacy of Ciltacabtagene Autoleucel Versus Standard-of-Care Treatments for Patients with Previously Treated Relapsed or Refractory Multiple Myeloma: A Matching-Adjusted Indirect Comparison.Advances in therapy2025name in title: ciltacabtagene autoleucel
PMID 40459151Long-Term (≥5-Year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple Myeloma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology2025cited by trial NCT03548207
PMID 40501515Ruxolitinib Is an Effective Therapy for Ciltacabtagene Autoleucel-Associated Parkinsonism in Multiple Myeloma.Journal of hematology2025name in title: ciltacabtagene autoleucel
PMID 40613875Survival Outcomes with Cilta-cel Versus Conventional Treatment Regimens for Patients with Lenalidomide-Refractory Multiple Myeloma Using Inverse Probability of Treatment Weighting.Advances in therapy2025cited by trial NCT04181827
PMID 40738883Activity of CAR-T cells and bispecific antibodies in multiple myeloma with extramedullary involvement.Blood cancer journal2025name in abstract: cilta-cel
PMID 40749169Sequential targeting in multiple myeloma: talquetamab, a GPRC5D bispecific antibody, as a bridge to BCMA CAR-T therapy.Blood2025name in abstract: ciltacabtagene autoleucel
PMID 40768190Comparative Effectiveness of Ciltacabtagene Autoleucel in CARTITUDE-4 Versus Real-World Physician's Choice of Therapy from the Flatiron Registry in Lenalidomide-Refractory Multiple Myeloma.Advances in therapy2025cited by trial NCT04181827
PMID 40875887Safety and efficacy of BCMA-directed chimeric antigen receptor T-cell therapy for the treatment of plasma cell leukemia.Blood advances2025name in abstract: ciltacabtagene autoleucel
PMID 41115887Chronic inflammatory demyelinating polyneuropathy (CIDP) after cilta-cel therapy.Blood cancer journal2025name in title: cilta-cel
PMID 41342049Chimeric Antigen Receptor T-Cell Therapy in Dialysis-Dependent Patients With Multiple Myeloma: Insights From a 5-Case Series.Kidney medicine2025name in abstract: ciltacabtagene autoleucel
PMID 38369805Outcomes in patients with multiple myeloma receiving salvage treatment after BCMA-specific CAR-T therapy: A retrospective analysis of LEGEND-2.British journal of haematology2024name in abstract: LCAR-B38M
PMID 38659046Long-term remission and survival in patients with relapsed or refractory multiple myeloma after treatment with LCAR-B38M CAR T cells: 5-year follow-up of the LEGEND-2 trial.Journal of hematology & oncology2024cited by trial NCT03090659
PMID 38697457Very unusual extremely high ferritin with cytokine release syndrome in a patient with hematological malignancy after experimental chimeric antigen receptor (CAR)-T-Cell therapy.Clinica chimica acta; international journal of clinical chemistry2024name in abstract: Carvykti
PMID 38713595FDA Approval Summary: Ciltacabtagene Autoleucel for Relapsed or Refractory Multiple Myeloma.Clinical cancer research : an official journal of the American Association for Cancer Research2024name in title: ciltacabtagene autoleucel
PMID 38776397Absolute lymphocyte count after BCMA CAR-T therapy is a predictor of response and outcomes in relapsed multiple myeloma.Blood advances2024name in abstract: ciltacabtagene autoleucel
PMID 38865661Indolent CD4+ CAR T-Cell Lymphoma after Cilta-cel CAR T-Cell Therapy.The New England journal of medicine2024name in title: cilta-cel
PMID 39100867Chimeric Antigen Receptor (CAR) T-Cell Therapy Use in Patients with Multiple Myeloma and Kidney Failure on Maintenance Hemodialysis: A Report of 2 Cases.Kidney medicine2024name in abstract: ciltacabtagene autoleucel
PMID 39110421Plain language summary of the CARTITUDE-4 study of ciltacabtagene autoleucel for the treatment of people with relapsed or refractory multiple myeloma.Future oncology (London, England)2024cited by trial NCT04181827
PMID 39162049Efficacy of CARVYKTI in CARTITUDE-4 versus other conventional treatment regimens for lenalidomide-refractory multiple myeloma using inverse probability of treatment weighting.Journal of comparative effectiveness research2024name in title: Carvykti
PMID 39234256Cost-per-responder analysis of patients with lenalidomide-refractory multiple myeloma receiving ciltacabtagene autoleucel in CARTITUDE-4.Frontiers in immunology2024cited by trial NCT04181827
PMID 39372422Case report: Treatment of parkinsonism secondary to ciltacabtagene autoleucel using a combination dopaminergic regimen.Frontiers in immunology2024name in title: ciltacabtagene autoleucel
PMID 39507461How we manage multiple myeloma with clonal hematopoiesis of indeterminate potential (CHIP): a case report.Annals of translational medicine2024name in abstract: ciltacabtagene autoleucel
PMID 35658469Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up.Journal of clinical oncology : official journal of the American Society of Clinical Oncology2023cited by trial NCT03548207
PMID 36095849Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents.Blood2023cited by trial NCT04133636
PMID 36269898Phase II, Open-Label Study of Ciltacabtagene Autoleucel, an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor-T-Cell Therapy, in Chinese Patients With Relapsed/Refractory Multiple Myeloma (CARTIFAN-1).Journal of clinical oncology : official journal of the American Society of Clinical Oncology2023cited by trial NCT03758417
PMID 36357295Patient Perceptions Regarding Ciltacabtagene Autoleucel Treatment: Qualitative Evidence From Interviews With Patients With Relapsed/Refractory Multiple Myeloma in the CARTITUDE-1 Study.Clinical lymphoma, myeloma & leukemia2023cited by trial NCT03548207
PMID 36546453Adjusted comparison of outcomes between patients from CARTITUDE-1 versus multiple myeloma patients with prior exposure to proteasome inhibitors, immunomodulatory drugs and anti-CD38 antibody from the prospective, multinational LocoMMotion study of real-world clinical practice.Haematologica2023cited by trial NCT03548207
PMID 37137553BCMA CAR-T induces complete and durable remission in refractory plasmablastic lymphoma.Journal for immunotherapy of cancer2023cited by trial NCT03548207
PMID 37270762Extrapolation of Survival Data Using a Bayesian Approach: A Case Study Leveraging External Data from Cilta-Cel Therapy in Multiple Myeloma.Oncology and therapy2023cited by trial NCT03090659
PMID 37272512Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma.The New England journal of medicine2023cited by trial NCT04181827
PMID 37999117Anti-B Cell Maturation Antigen Chimeric Antigen Receptor T Cell Therapy for the Treatment of AL Amyloidosis and Concurrent Relapsed/Refractory Multiple Myeloma: Preliminary Efficacy and Safety.Current oncology (Toronto, Ont.)2023name in abstract: cilta-cel
PMID 34822128Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 vs Physician's Choice of Therapy in the Long-Term Follow-Up of POLLUX, CASTOR, and EQUULEUS Clinical Trials for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma.Clinical drug investigation2022name in title: ciltacabtagene autoleucel
PMID 35764490Matching-Adjusted Indirect Treatment Comparison to Assess the Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 Versus Belantamab Mafodotin in DREAMM-2, Selinexor-Dexamethasone in STORM Part 2, and Melphalan Flufenamide-Dexamethasone in HORIZON for the Treatment of Patients With Triple-Class Exposed Relapsed or Refractory Multiple Myeloma.Clinical lymphoma, myeloma & leukemia2022name in title: ciltacabtagene autoleucel
PMID 35794616Four-year follow-up of LCAR-B38M in relapsed or refractory multiple myeloma: a phase 1, single-arm, open-label, multicenter study in China (LEGEND-2).Journal of hematology & oncology2022cited by trial NCT03090659
PMID 36052883Ciltacabtagene autoleucel in patients with relapsed/refractory multiple myeloma: CARTITUDE-1 (phase 2) Japanese cohort.Cancer science2022name in title: ciltacabtagene autoleucel
PMID 36204820Population-based cellular kinetic characterization of ciltacabtagene autoleucel in subjects with relapsed or refractory multiple myeloma.Clinical and translational science2022cited by trial NCT03548207
PMID 36215989Health-related quality of life in patients given ciltacabtagene autoleucel for relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b-2, open-label study.The Lancet. Haematology2022cited by trial NCT03548207
PMID 36496425Five-year remission without disease progression in a patient with relapsed/refractory multiple myeloma with extramedullary disease treated with LCAR-B38M chimeric antigen receptor T cells in the LEGEND-2 study: a case report.Journal of medical case reports2022name in title: LCAR-B38M
PMID 34175021Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study.Lancet (London, England)2021cited by trial NCT03548207
PMID 34256668Matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma.Current medical research and opinion2021name in title: ciltacabtagene autoleucel
PMID 34893771Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy.Nature medicine2021cited by trial NCT03548207
PMID 30988175Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed/refractory multiple myeloma.Proceedings of the National Academy of Sciences of the United States of America2019name in abstract: LCAR-B38M
PMID 30572922A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma.Journal of hematology & oncology2018cited by trial NCT03090659

Other papers

Preclinical studies, reviews and other papers that name it, newest 100 shown.

PubMedTitleJournalYearLinked by
PMID 39410883Neurotoxicity associated with chimeric antigen receptor T-cell therapy: a real-world study leveraging the FDA Adverse Event Reporting System.Expert opinion on drug safety2026name in abstract: ciltacabtagene autoleucel
PMID 40994343Hepatitis E virus infections in people with multiple myeloma: an emerging challenge in the era of immunotherapeutic approaches.Haematologica2026name in abstract: ciltacabtagene autoleucel
PMID 41191534Long-term remission after cilta-cel in multiple myeloma is linked to diverse T cells and low myeloid suppression.Blood advances2026name in title: cilta-cel
PMID 41349540A longitudinal single-cell atlas to predict outcome and toxicity after BCMA-directed CAR T cell therapy in multiple myeloma.Cancer cell2026name in abstract: ciltacabtagene autoleucel
PMID 41391508Immune Effector Cell-Associated HLH-Like Syndrome (IEC-HS) in CAR-T and TCE-Treated Myeloma and B-Cell Malignancies: Insights from a Pharmacovigilance Study.Transplantation and cellular therapy2026name in abstract: ciltacabtagene autoleucel
PMID 41396346Cost-Effectiveness of Chimeric Antigen Receptor (CAR) T-Cell Therapy for Blood Cancers: An Updated Systematic Review.PharmacoEconomics - open2026name in abstract: ciltacabtagene autoleucel
PMID 41396414Characteristics and utilization of the three BCMA-targeted therapies in multiple myeloma.International journal of hematology2026name in abstract: ciltacabtagene autoleucel
PMID 414286222025 Update of Cellular Immunotherapy for Plasma Cell Disorders.Turkish journal of haematology : official journal of Turkish Society of Haematology2026name in abstract: cilta-cel
PMID 41448297Chimeric antigen receptor T-cell therapy and immune effector cell-associated neurotoxicity syndrome: A meta-analysis.Critical reviews in oncology/hematology2026name in abstract: ciltacabtagene autoleucel
PMID 41455802Feasibility of outpatient administration of ciltacabtagene autoleucel and reduction in healthcare utilization cost: the Vanderbilt experience.Bone marrow transplantation2026name in title: ciltacabtagene autoleucel
PMID 41455805CAR T-cells in multiple myeloma: the race to the start line.Bone marrow transplantation2026name in abstract: ciltacabtagene autoleucel
PMID 41485660Bridging discovery and therapy in precision medicine-Phage display as a catalyst for nanobody innovation: A review.International journal of biological macromolecules2026name in abstract: ciltacabtagene autoleucel
PMID 41540109CD4+ T cells mediate CAR-T cell-associated immune-related adverse events after BCMA CAR-T cell therapy.Nature medicine2026name in abstract: ciltacabtagene autoleucel
PMID 41547065Intra-procedure white blood cell monitoring as a predictor of collection efficiency in mononuclear cell apheresis.Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis2026name in abstract: Carvykti
PMID 41563628Antibody-Drug Conjugates, T-Cell Engager Bispecific Antibodies and Chimeric Antigen Receptor T Cells for Multiple Myeloma: What's the Current Status?Targeted oncology2026name in abstract: ciltacabtagene autoleucel
PMID 41610427Dual-antigen-targeting T-cell immunotherapies in MM: circumventing tumor heterogeneity and preventing antigen escape.Blood2026name in abstract: ciltacabtagene autoleucel
PMID 41616604Pretreatment physical function as a risk factor for movement and neurocognitive treatment-emergent events (MNTs) in multiple myeloma (MM) patients treated with cilta-cel.Journal of the neurological sciences2026name in title: cilta-cel
PMID 41687609The cellular orchestra of CAR T success.Cancer cell2026name in abstract: cilta-cel
PMID 41703026MyCARdiac score: integrating cardiac imaging and biomarkers to predict outcomes in RRMM patients receiving cilta-cel.Leukemia2026name in title: cilta-cel
PMID 41720163Musculoskeletal Adverse Events Following BCMA CAR T-Cell Therapy in Multiple Myeloma: Clinical Characteristics and Immune Correlates.Transplantation and cellular therapy2026name in abstract: ciltacabtagene autoleucel
PMID 41721717Efficacy and Safety Comparisons of Four Approved Chimeric Antigen Receptor T-Cell Therapies in Multiple Myeloma.Hematological oncology2026name in abstract: ciltacabtagene autoleucel
PMID 41734332Comparative cost per responder analysis of ciltacabtagene autoleucel and real-world standard of care therapy in patients with lenalidomide-refractory multiple myeloma.Expert review of pharmacoeconomics & outcomes research2026name in title: ciltacabtagene autoleucel
PMID 41744844BCMA-Directed CAR T-Cell Therapy in Patients with Relapsed/Refractory Multiple Myeloma and Renal Impairment.Current oncology (Toronto, Ont.)2026name in abstract: ciltacabtagene autoleucel
PMID 41827691Outpatient Versus Inpatient Administration of Ciltacabtagene Autoleucel in Multiple Myeloma: A Systematic Review of Clinical, Economic, and Humanistic Outcomes.Cancers2026name in title: ciltacabtagene autoleucel
PMID 41848013Real-world healthcare resource utilization and clinical outcomes among patients with relapsed/refractory multiple myeloma receiving ciltacabtagene autoleucel after four or more prior lines of therapy in inpatient versus outpatient settings.Journal of medical economics2026name in title: ciltacabtagene autoleucel
PMID 41870621Predictors of 30-day readmissions post-CAR-T in patients with relapsed/refractory multiple myeloma using the United States nationwide readmission database.Annals of hematology2026name in abstract: cilta-cel
PMID 41874852FREEDOMM: Fifth-Line or Later Real-World Evaluation of Efficacy and Disease Outcomes in Multiple Myeloma with Ciltacabtagene Autoleucel: Treatment-Free Interval and Overall Survival in the USA.Advances in therapy2026name in title: ciltacabtagene autoleucel
PMID 41886632Non-ICANS neurologic toxicity after BCMA CAR-T therapy: a systematic review and meta-analysis of 4630 patients with multiple myeloma.Blood advances2026name in abstract: ciltacabtagene autoleucel
PMID 41894686Dexamethasone prophylaxis for excessive lymphocyte expansion after cilta-cel in multiple myeloma.Blood advances2026name in title: cilta-cel
PMID 41899614Real-World Experience with Approved CAR T-Cell Therapies Ciltacabtagene Autoleucel and Idecabtagene Vicleucel in 1272 Relapsed/Refractory Multiple Myeloma Patients.Cancers2026name in title: ciltacabtagene autoleucel
PMID 41935039Dynamics of BCMA expression in patients with relapsed/refractory multiple myeloma receiving BCMA-directed CAR-T therapy.Blood cancer journal2026name in abstract: ciltacabtagene autoleucel
PMID 41951449Infections Post-CAR-T Therapy: A Real-World Pharmacovigilance Analysis of the FDA Adverse Event Reporting System (FAERS) Database.Clinical therapeutics2026name in abstract: cilta-cel
PMID 41961998Diagnosis and management of immune effector cell-associated enterocolitis after ciltacabtagene autoleucel.Blood advances2026name in title: ciltacabtagene autoleucel
PMID 41963287Association of ciltacabtagene autoleucel with immune effector cell-associated enterocolitis: insights from a large national database.Blood cancer journal2026name in title: ciltacabtagene autoleucel
PMID 42000954Real-World Description of Non-ICANS Neurologic Events Among Patients with Relapsed or Refractory Multiple Myeloma Treated with Ciltacabtagene Autoleucel Using Two Large US Databases.Oncology and therapy2026name in title: ciltacabtagene autoleucel
PMID 42057607Clinical outcomes with ciltacabtagene autoleucel among patients with relapsed/refractory multiple myeloma after four or more prior lines of therapy overall and among subgroups based on age, frailty, and CRAB symptoms.Current medical research and opinion2026name in title: ciltacabtagene autoleucel
PMID 42086512Hemophagocytic Lymphohistiocytosis After CAR T-Cell Therapy: A Systematic Review and Meta-Analysis.American journal of hematology2026name in abstract: ciltacabtagene autoleucel
PMID 42115674Patient-reported outcomes after idecabtagene vicleucel vs. ciltacabtagene autoleucel CAR-T for multiple myeloma.Bone marrow transplantation2026name in title: ciltacabtagene autoleucel
PMID 42144192Impact of Renal Impairment and Lymphodepletion Regimen on Outcomes after CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma.Transplantation and cellular therapy2026name in abstract: ciltacabtagene autoleucel
PMID 42161729Non-ICANS Neurologic Events in Patients With Relapsed/Refractory Multiple Myeloma Treated With Ciltacabtagene Autoleucel: Clinical Presentation and Management in CARTITUDE Studies.Clinical lymphoma, myeloma & leukemia2026name in title: ciltacabtagene autoleucel
PMID 42163304Standard-of-care ciltacabtagene autoleucel in earlier versus later lines of therapy for relapsed or refractory multiple myeloma: a nationwide registry analysis.Journal of hematology & oncology2026name in title: ciltacabtagene autoleucel
PMID 42163771[18F]Fluorodeoxyglucose-PET/MRI-based response assessment following BCMA-directed CAR-T-cell therapy with ciltacabtagene autoleucel in relapsed/refractory multiple myeloma.Haematologica2026name in title: ciltacabtagene autoleucel
PMID 42169674Real-world outcomes of cilta-cel versus BCMA-targeting bispecific antibodies in relapsed/refractory multiple myeloma.Leukemia & lymphoma2026name in title: cilta-cel
PMID 42227005Real-World Incidence and Management of Non-Immune Effector Cell-Associated Neurotoxicity Syndrome Neurologic Events Following Ciltacabtagene Autoleucel in Multiple Myeloma.Clinical epidemiology2026name in title: ciltacabtagene autoleucel
PMID 42252797Cost-effective analysis of teclistamab and daratumumab versus ciltacabtagene autoleucel in relapsed multiple myeloma.British journal of haematology2026name in title: ciltacabtagene autoleucel
PMID 42260185Does ciltacabtagene autoleucel have a future in multiple myeloma?Nature reviews. Clinical oncology2026name in title: ciltacabtagene autoleucel
PMID 42345308A systematic review of indirect treatment comparisons among recently approved chimeric antigen receptor T-cell and bispecific antibody therapies for triple-class exposed relapsed/refractory multiple myeloma.Current medical research and opinion2026name in abstract: ciltacabtagene autoleucel
PMID 42361980Real-World Safety, Efficacy, and Immune Recovery Following Out-of-Specification Ciltacabtagene Autoleucel in Multiple Myeloma.Transplantation and cellular therapy2026name in title: ciltacabtagene autoleucel
PMID 42365547IMMPACT-MM: Insights into Multiple Myeloma Patient Outcomes following Early-Line Cilta-cel Treatment.Oncology and therapy2026name in title: cilta-cel
PMID 42388416Transitioning CAR-T therapy for multiple myeloma to the outpatient setting: First clinical insights with cilta-cel in Germany.HemaSphere2026name in title: cilta-cel
PMID 42418682Rapid peak cilta-cel expansion is associated with delayed neurotoxicity in multiple myeloma.Blood2026name in title: cilta-cel
PMID 42449019Ciltacabtagene autoleucel heralds the arrival of fixed-duration therapies in myeloma.Nature reviews. Clinical oncology2026name in title: ciltacabtagene autoleucel
PMID 42449020The future of ciltacabtagene autoleucel in multiple myeloma has just begun.Nature reviews. Clinical oncology2026name in title: ciltacabtagene autoleucel
PMID 42449578Low-Frequency PPM1D Gene Mutations Affect Treatment Response to BCMA-Targeted CAR T-Cell Therapy in Multiple Myeloma.Cancers2026name in abstract: ciltacabtagene autoleucel
PMID 42471153Transfusion support after CAR-T cell therapy: Real-world patterns across commercial products and disease groups.Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine2026name in abstract: ciltacabtagene autoleucel
PMID 42512374Efficacy and Safety of CAR-T Cell Therapy and Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma with Renal Impairment: A Propensity Score-Matched Analysis.Cancers2026name in abstract: ciltacabtagene autoleucel
PMID 42518303Real-world analyses of bispecific antibodies and CAR-T cell therapy in relapsed or refractory multiple myeloma: a global TriNetX discovery and contemporary validation cohort.Leukemia & lymphoma2026name in abstract: cilta-cel
PMID 42518817Optimizing ciltacabtagene autoleucel outcomes: real-world experience and best practices from a single academic center.Frontiers in oncology2026name in title: ciltacabtagene autoleucel
PMID 42525783Robust CD4+ CAR T cell expansion is associated with non-ICANS neurotoxicities after ciltacabtagene autoleucel in patients with multiple myeloma.Science translational medicine2026name in title: ciltacabtagene autoleucel
PMID 42642985Real-world treatment patterns and outcomes of patients treated with commercial chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma.Current medical research and opinion2026name in abstract: ciltacabtagene autoleucel
PMID 42644320Real-world outcomes of ide-cel and cilta-cel in relapsed/refractory multiple myeloma: A nationwide, retrospective analysis in Austria.British journal of haematology2026name in title: cilta-cel
PMID 42660229Adaptive Bridging and Holding Therapy Frequently Reduces Tumor Burden and Is Associated With Reduced Toxicity After CAR-T Cell Therapy in Multiple Myeloma: A Single-Center Real-World Experience.Transplantation and cellular therapy2026name in abstract: ciltacabtagene autoleucel
PMID 42675051Correction: Safety and efficacy of ciltacabtagene autoleucel for relapsed/refractory multiple myeloma: a CIBMTR study.Blood cancer journal2026name in title: ciltacabtagene autoleucel
PMID 42705499Delayed Neurologic and Enterocolitis Reporting Patterns for Ciltacabtagene Autoleucel Versus Idecabtagene Vicleucel in EudraVigilance.Transplantation and cellular therapy2026name in title: ciltacabtagene autoleucel
PMID 42724501Long-term safety and efficacy of BCMA-directed CAR T-cell therapies in multiple myeloma: comparative insights from Cilta-cel, Ide-cel, Anito-cel, and FCARH143.Translational cancer research2026name in title: cilta-cel
PMID 42727844Cost-Effectiveness of Cilta-cel in Lenalidomide-Refractory Multiple Myeloma: An Analysis of the CARTITUDE-4 Trial.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research2026name in title: cilta-cel
PMID 42728267Prophylactic dexamethasone at the time of absolute lymphocyte expansion does not mitigate risk or event-free survival for immune effector cell associated delayed neurotoxicity.Blood cancer journal2026name in abstract: ciltacabtagene autoleucel
PMID 42759984Gene regulatory elements determine efficacy of BCMA-targeted CAR-T cell products.Journal for immunotherapy of cancer2026name in abstract: ciltacabtagene autoleucel
PMID 42778764Persistence of mucosal CAR-T cells and inflammatory remodeling in enterocolitis associated with BCMA CAR-T cell therapy.Nature medicine2026name in abstract: ciltacabtagene autoleucel
PMID 42779338Efficacy and safety of frail patients treated with ciltacabtagene autoleucel in the real world: A Center for International Blood and Marrow Transplant Research analysis.Cancer2026name in title: ciltacabtagene autoleucel
PMID 42841179BCMA-Targeted Immunotherapy in Early Relapsed/Refractory Multiple Myeloma: Mechanisms, Clinical Evidence, and Practical Management.European journal of haematology2026name in abstract: ciltacabtagene autoleucel
PMID 42844619T-cell-redirecting therapies in early relapsed multiple myeloma: a systematic review and network meta-analysis.Journal of hematology & oncology2026name in abstract: ciltacabtagene autoleucel
PMID 42844744Immune effector cell-associated neurotoxicity syndrome in hematological malignancy patients treated with CAR-T cell: A systematic review.Journal of investigative medicine : the official publication of the American Federation for Clinical Research2026name in abstract: ciltacabtagene autoleucel
PMID 42868529Cost-Effectiveness of AI-Powered Decentralized Production for Advanced Therapies in the Hospital-Generated Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma From a German Hospital Perspective: Early Health Technology Assessment Study.JMIR cancer2026name in abstract: ciltacabtagene autoleucel
PMID 42879175Cilta-cel CAR T-cell expansion and neurotoxicity.Blood2026name in title: cilta-cel
PMID 42889616Reshaping the definition of high-risk disease in the immune effector therapy era in multiple myeloma.Frontiers in oncology2026name in abstract: ciltacabtagene autoleucel
PMID 42901918The EF1α promoter of cilta-cel drives a highly effective GZMK+ transcriptional program.Nature communications2026name in title: cilta-cel
PMID 42908664Comparative real-world pharmacovigilance analysis of adverse event signals associated with six approved CAR-T products using the FAERS database.Frontiers in pharmacology2026name in abstract: Carvykti
PMID 42988507The Bottom Line: OOS Cilta-cel in MM.Transplantation and cellular therapy2026name in title: cilta-cel
PMID 42991680Orthopnea From Phrenic Nerve Palsy After Ciltacabtagene Autoleucel CAR T-Cell Therapy in a Patient With Multiple Myeloma.Journal of the advanced practitioner in oncology2026name in title: ciltacabtagene autoleucel
PMID 42992382Correction to "Efficacy and safety of frail patients treated with ciltacabtagene autoleucel in the real world: A Center for International Blood and Marrow Transplant Research analysis".Cancer2026name in title: ciltacabtagene autoleucel
PMID 38718775Toxicity of CAR T-Cell Therapy for Multiple Myeloma.Acta haematologica2025name in abstract: ciltacabtagene autoleucel
PMID 39373355B-Cell Maturation Antigen-Directed Immunotherapies for the Treatment of Relapsed/Refractory Multiple Myeloma: A Review of the Literature and Implications for Clinical Practice.The Annals of pharmacotherapy2025name in abstract: ciltacabtagene autoleucel
PMID 39672542Neurotoxicity and Rare Adverse Events in BCMA-Directed CAR T Cell Therapy: A Comprehensive Analysis of Real-World FAERS Data.Transplantation and cellular therapy2025name in abstract: ciltacabtagene autoleucel
PMID 39729503BCMA-directed CAR T-cell therapy in patients with multiple myeloma and CNS involvement.Blood advances2025name in abstract: ciltacabtagene autoleucel
PMID 39748220Update on B-cell maturation antigen-directed therapies in AL amyloidosis.British journal of haematology2025name in abstract: ciltacabtagene autoleucel
PMID 39779930T cell malignancies after CAR T cell therapy in the DESCAR-T registry.Nature medicine2025name in abstract: ciltacabtagene autoleucel
PMID 39822585Idecabtagene vicleucel or ciltacabtagene autoleucel for relapsed or refractory multiple myeloma: An international multicenter study.HemaSphere2025name in title: ciltacabtagene autoleucel
PMID 39915676International approvals of cilta-cel: a lens on CAR T cell regulation.Nature reviews. Clinical oncology2025name in title: cilta-cel
PMID 39990276Ciltacabtagene Autoleucel for the Treatment of Relapsed/Refractory Multiple Myeloma: Efficacy, Safety, and Place in Therapy.Cancer management and research2025name in title: ciltacabtagene autoleucel
PMID 40053892Erratum: Comparison of Standard-of-Care Idecabtagene Vicleucel and Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology2025name in title: ciltacabtagene autoleucel
PMID 40095642Current Treatment Strategies for Multiple Myeloma at First Relapse.Journal of clinical medicine2025name in abstract: cilta-cel
PMID 40098471Establishing a successful outpatient CAR T-Cell program with cilta-cel: real-world experience from an expert roundtable.Future oncology (London, England)2025name in title: cilta-cel
PMID 40225701Economic Impact of Elranatamab for Treatment of Patients with Relapsed or Refractory Multiple Myeloma.ClinicoEconomics and outcomes research : CEOR2025name in abstract: ciltacabtagene autoleucel
PMID 40246942CAR-T for multiple myeloma: practice pearls.Bone marrow transplantation2025name in abstract: ciltacabtagene autoleucel
PMID 40295321The management of multiple myeloma patients accompanied with disseminated intravascular coagulation before receiving LCAR-B38M therapy.Discover oncology2025name in title: LCAR-B38M
PMID 40334078Intrathecal chemotherapy for ciltacabtagene autoleucel-associated movement and neurocognitive toxicity.Blood advances2025name in title: ciltacabtagene autoleucel
PMID 40346502Hematologic and lymphatic disorders associated with chimeric antigen receptor T-cell therapy: a pharmacovigilance analysis of the FDA adverse event reporting system (FAERS) database.BMC cancer2025name in abstract: cilta-cel
PMID 40474425An exploration of the initiation time and patient selection of PD-1 inhibitors/PD-1 inhibitors combined with chemotherapy as salvage therapy in R/R DLBCL patients after anti-CD19-CAR T-cell therapy.Cell transplantation2025name in abstract: LCAR-B38M
PMID 40501407Cilta-cel CAR T cells as an effective and well tolerated treatment for POEMS: a case study.Haematologica2025name in title: cilta-cel

NIH grants

ProjectTitleOrganisationPIYearsLinked by
R01CA316736Mechanisms of BCMA CAR-T-mediated enteritis in multiple myeloma patientsUNIVERSITY OF CALIFORNIA, SAN FRANCISCOOH, DAVID YOONSUK2026–2026name in abstract: cilta-cel

Notes

Bi-epitopic anti-BCMA VHH CAR. LCAR-B38M (Legend, China) and JNJ-68284528 treated as one product.

How to cite

ciltacabtagene autoleucel (AXP000018.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000018.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.